These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34634662)

  • 1. Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma.
    Kumar V; Wang Q; Sethi B; Lin F; Kumar V; Coulter DW; Dong Y; Mahato RI
    Biomaterials; 2021 Nov; 278():121138. PubMed ID: 34634662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ApoE mimetic peptide targeted nanoparticles carrying a BRD4 inhibitor for treating Medulloblastoma in mice.
    Wang Q; Kumar V; Lin F; Sethi B; Coulter DW; McGuire TR; Mahato RI
    J Control Release; 2020 Jul; 323():463-474. PubMed ID: 32380205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting BRD4 and PI3K signaling pathways for the treatment of medulloblastoma.
    Sethi B; Kumar V; Jayasinghe TD; Dong Y; Ronning DR; Zhong HA; Coulter DW; Mahato RI
    J Control Release; 2023 Feb; 354():80-90. PubMed ID: 36599397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymeric Micellar Delivery of Novel Microtubule Destabilizer and Hedgehog Signaling Inhibitor for Treating Chemoresistant Prostate Cancer.
    Yang R; Chen H; Guo D; Dong Y; Miller DD; Li W; Mahato RI
    J Pharmacol Exp Ther; 2019 Sep; 370(3):864-875. PubMed ID: 30996033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis.
    Kumar V; Dong Y; Kumar V; Almawash S; Mahato RI
    Theranostics; 2019; 9(25):7537-7555. PubMed ID: 31695785
    [No Abstract]   [Full Text] [Related]  

  • 6. Engineered biomimetic nanoparticle for dual targeting of the cancer stem-like cell population in sonic hedgehog medulloblastoma.
    Kim J; Dey A; Malhotra A; Liu J; Ahn SI; Sei YJ; Kenney AM; MacDonald TJ; Kim Y
    Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24205-24212. PubMed ID: 32934143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
    Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
    Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SF2523 inhibits human chondrosarcoma cell growth in vitro and in vivo.
    Zhu JX; Xiao JR
    Biochem Biophys Res Commun; 2019 Apr; 511(3):559-565. PubMed ID: 30824188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glabrescione B delivery by self-assembling micelles efficiently inhibits tumor growth in preclinical models of Hedgehog-dependent medulloblastoma.
    Infante P; Malfanti A; Quaglio D; Balducci S; De Martin S; Bufalieri F; Mastrotto F; Basili I; Garofalo M; Lospinoso Severini L; Mori M; Manni I; Moretti M; Nicoletti C; Piaggio G; Caliceti P; Botta B; Ghirga F; Salmaso S; Di Marcotullio L
    Cancer Lett; 2021 Feb; 499():220-231. PubMed ID: 33249196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.
    Bolin S; Borgenvik A; Persson CU; Sundström A; Qi J; Bradner JE; Weiss WA; Cho YJ; Weishaupt H; Swartling FJ
    Oncogene; 2018 May; 37(21):2850-2862. PubMed ID: 29511348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo.
    Jonchere B; Williams J; Zindy F; Liu J; Robinson S; Farmer DM; Min J; Yang L; Stripay JL; Wang Y; Freeman BB; Yu J; Shelat AA; Rankovic Z; Roussel MF
    Mol Cancer Ther; 2023 Jan; 22(1):37-51. PubMed ID: 36318650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.
    Kool M; Jones DT; Jäger N; Northcott PA; Pugh TJ; Hovestadt V; Piro RM; Esparza LA; Markant SL; Remke M; Milde T; Bourdeaut F; Ryzhova M; Sturm D; Pfaff E; Stark S; Hutter S; Seker-Cin H; Johann P; Bender S; Schmidt C; Rausch T; Shih D; Reimand J; Sieber L; Wittmann A; Linke L; Witt H; Weber UD; Zapatka M; König R; Beroukhim R; Bergthold G; van Sluis P; Volckmann R; Koster J; Versteeg R; Schmidt S; Wolf S; Lawerenz C; Bartholomae CC; von Kalle C; Unterberg A; Herold-Mende C; Hofer S; Kulozik AE; von Deimling A; Scheurlen W; Felsberg J; Reifenberger G; Hasselblatt M; Crawford JR; Grant GA; Jabado N; Perry A; Cowdrey C; Croul S; Zadeh G; Korbel JO; Doz F; Delattre O; Bader GD; McCabe MG; Collins VP; Kieran MW; Cho YJ; Pomeroy SL; Witt O; Brors B; Taylor MD; Schüller U; Korshunov A; Eils R; Wechsler-Reya RJ; Lichter P; Pfister SM;
    Cancer Cell; 2014 Mar; 25(3):393-405. PubMed ID: 24651015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
    Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
    Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of BRD4 and PI3K by SF2523 suppresses human prostate cancer cell growth in vitro and in vivo.
    Shen G; Jiang M; Pu J
    Biochem Biophys Res Commun; 2018 Jan; 495(1):567-573. PubMed ID: 29133261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
    Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
    PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of pseudolaric acid B as a novel Hedgehog pathway inhibitor in medulloblastoma.
    Wei SF; He DH; Zhang SB; Lu Y; Ye X; Fan XZ; Wang H; Wang Q; Liu YQ
    Biochem Pharmacol; 2021 Aug; 190():114593. PubMed ID: 33964282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming resistance to Sonic Hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma.
    Pambid MR; Berns R; Adomat HH; Hu K; Triscott J; Maurer N; Zisman N; Ramaswamy V; Hawkins CE; Taylor MD; Dunham C; Guns E; Dunn SE
    Pediatr Blood Cancer; 2014 Jan; 61(1):107-15. PubMed ID: 23940083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
    Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X
    Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via JNK-dependent but p53-independent mechanism.
    Azatyan A; Gallo-Oller G; Diao Y; Selivanova G; Johnsen JI; Zaphiropoulos PG
    Cancer Lett; 2019 Feb; 442():341-350. PubMed ID: 30447254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
    Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
    Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.